Krystal's manufacturing milestone moves it closer to commercial readiness

US gene therapy company Krystal Biotech (Nasdaq: KRYS) has finished building its manufacturing facility close to its Pittsburgh headquarters.

The site will support clinical and commercial manufacturing of Krystal’s lead product candidate, KB103, for dystrophic epidermolysis bullosa (DEB), and will officially open early this year following completion of the first engineering run.

Krish Krishnan, chairman and chief executive officer of Krystal, which is developing topical and intradermal off-the-shelf treatments for rare dermatological diseases, said: “Our development of internal manufacturing capabilities bolsters our position for commercial readiness as we execute on our vision to bring our therapies to the patient communities in need.”